Cartesian Therapeutics (RNAC) FCF Margin (2015 - 2026)
Cartesian Therapeutics' (RNAC) quarterly FCF Margin came in at 28412.82% in Q1 2026, down 2621437.0% year-on-year from N/an in Q1 2025, and down 1067.08% on a QoQ basis from 2434.53% in Q4 2025.
Cartesian Therapeutics (RNAC) FCF Margin (2015 - 2026) Analysis & Trends
Cartesian Therapeutics (RNAC) has 12 years of FCF Margin data on file, last reported at 28412.82% in Q1 2026.
- On a quarterly basis, FCF Margin fell 2621437.0% year-over-year to 28412.82% in Q1 2026; TTM through Mar 2026 was 7548.68%, a 745091.0% decrease from a year earlier, with the FY2025 full-year figure at 2838.58%, down 277451.0% from the prior year.
- FCF Margin for Q1 2026 stood at 28412.82%, down from 2434.53% in the prior quarter.
- Over the last five years, FCF Margin for RNAC reached as high as 891.99% in Q4 2024 and fell as low as 28412.82% in Q1 2026.
- Historically, FCF Margin has averaged 2382.75% across 5 years, with a median of 145.36% in 2023.
- Across the five-year window, FCF Margin surged 117446 bps in 2024 and sank 2621437 bps in 2026, its largest moves.
- Year by year, FCF Margin stood at 76.84% in 2022, then plunged by 268 bps to 282.47% in 2023, then soared by 416 bps to 891.99% in 2024, then tumbled by 373 bps to 2434.53% in 2025, then sank by 1067 bps to 28412.82% in 2026.
- Per Business Quant data, the three most recent FCF Margin figures were 28412.82% in Q1 2026, 2434.53% in Q4 2025, and 2198.45% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cartesian Therapeutics | 226.07 Mn | 226.07 Mn | - | -28,412.82% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28,412.82% |
| Dec 31, 2025 | -2,434.53% |
| Mar 31, 2025 | -2,198.45% |
| Dec 31, 2024 | 891.99% |
| Jun 30, 2024 | -50.00% |
| Mar 31, 2024 | -272.55% |
| Dec 31, 2023 | -282.47% |
| Sep 30, 2023 | -140.93% |
| Jun 30, 2023 | -186.95% |
| Mar 31, 2023 | -149.80% |
| Dec 31, 2022 | -76.84% |
| Sep 30, 2022 | 21.86% |
| Jun 30, 2022 | -31.83% |
| Mar 31, 2022 | -35.16% |
| Dec 31, 2021 | -108.65% |
| Sep 30, 2021 | -41.43% |
| Jun 30, 2021 | -33.88% |
| Mar 31, 2021 | -110.03% |
| Dec 31, 2020 | -55.47% |
| Sep 30, 2020 | 1,406.50% |